Pixium-Vision S.A., a privately funded Paris-based ophthalmic company, has announced the close of a EUR15 million Series A extension financing to fund the development of their lead “Intelligent Retinal Implant System” (IRIS). The investment, led by Sofinnova Partners will be used “to advance the development of Pixium’s IRIS retinal implant systems for patients who have lost their sight through degenerative conditions of the eye, such as retinitis pigmentosa and macular degeneration”. According to the company, Pixium’s first device, IRIS1, uses an epi-retinal implant and is currently in clinical trials with the goal of obtaining CE Mark. IRIS2, a second generation system is billed as offering improved visual acuity and featuring breakthrough technologies, while IRIS3 continues the strategy by building in further technological advances developed in recent years. Other investors in the ÃƒÂ¢Ã¢â‚¬Å¡Ã‚Â¬15M round include Bpifrance, through the InnoBio fund, Omnes Capital and Abingworth LLP.